HALO News and Press, Halozyme Therapeutics Inc. From 05/07/20

SAN DIEGO , May 7, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), will participate in the Bank of America Securities 2020 Healthcare Conference. This conference is being hosted virtually. Dr. Helen Torley , president and chief executive officer, will provide an overview...

SAN DIEGO , May 1, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for DARZALEX FASPRO ™ (daratumumab hyaluronidase human- f...

The FDA approves a subcutaneous formulation of Johnson & Johnson's ( JNJ -1.9% ) multiple myeloma med Darzalex (daratumumab). Originally, the CD38-directed cytolytic antibody was administered via intravenous infusion. More news on: Johnson & Johnson, Halozyme Therapeutics, Inc....

SAN DIEGO , April 30, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen-Cilag International NV (Janssen)  received a Committee for Medicinal Products for Human Use (CHMP) Positive Opinion from the European Medicines Agency (EMA) recommending...

SAN DIEGO , April 28, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2020 on Monday, May 11 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will l...

Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceutical K.K. has filed a marketing application in Japan for a subcutaneous formulation of multiple myeloma med Darzalex (daratumumab). More news on: Johnson & Johnson, Halozyme Therapeutics, Inc., Healthcare stocks news, Stocks o...

SAN DIEGO , April 26, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) by Janssen Pharmaceutical K.K. (Janssen) seeking approval of a new subcutaneous (S...

SAN DIEGO , April 3, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that due to the emerging public health impact of the coronavirus outbreak (COVID-19), to support the health and well-being of our employees and stockholders, and to comply with the S...

Today, we will see why Halozyme Therapeutics ( HALO ) is an attractive pick in March 2020. Company overview Halozyme Therapeutics is a biopharmaceutical company that is leveraging its Enhanze drug delivery technology in collaboration with other pharmaceutical companies to develop and com...

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...